drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Autologous/allogeneic T cells engineered via lentiviral transduction to express a CAR targeting BCMA; IV infusion at 2×10^6–1×10^7 CAR-T/kg; designed to kill BCMA+ plasma cells/myeloma cells through CAR-triggered cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous or allogeneic T cells are lentivirally engineered to express an anti-BCMA chimeric antigen receptor that recognizes BCMA on malignant plasma cells; CAR engagement activates T cells to proliferate and kill target cells via perforin/granzyme release and cytokine-mediated immune effects, leading to elimination of BCMA-positive myeloma cells.
drug_name
BCMA-directed CAR T cells
nct_id_drug_ref
NCT06849921